The effect of metformin on mortality and severity in COVID-19 patients with diabetes mellitus.
The effect of metformin on mortality and severity in COVID-19 patients with diabetes mellitus.
复制标题
DOI：
10.1016/j.diabres.2021.108977
复制
发表时间：
2021-08
影响因子：
5.1
通讯作者：
Zhang K
中科院分区：
文献类型：
--
作者：
Yang W;Sun X;Zhang J;Zhang K
COVID-19 已在全球范围内传播，对大多数国家产生了严重影响，而我们对患有糖尿病的 COVID-19 患者的治疗策略仍然有限。最近，该字段添加了一些新信息。我们进行了这项更新的荟萃分析，以揭示二甲双胍对患有糖尿病的 COVID-19 患者的潜在影响。我们检索了 PubMed、Embase 和 CNKI（中国国家知识基础设施）数据库中的所有文章。使用与 95% 置信区间 (95% CI) 相对应的比值比 (OR) 来评估二甲双胍对患有糖尿病的 COVID-19 患者的效果。研究之间的统计异质性通过 Q 检验和 I2 统计进行评估。我们收集了 17 项研究，其中包括 20,719 名患有糖尿病的 COVID-19 患者。我们的结果发现，二甲双胍可显着降低患有糖尿病的 COVID-19 患者的死亡率和严重程度（对于死亡率，OR=0.64，95% CI=0.51–0.79；对于严重程度，OR=0.81，95% CI=0.66–0.99）。我们的荟萃分析表明，二甲双胍治疗可能使 T2DM 患者受益，无论是死亡率还是严重程度。然而，应密切监测重症 COVID-19 患者是否出现乳酸酸中毒、酸中毒和肾功能下降。
COVID-19 has spread globally with heavy impact on most countries and our therapeutic strategies in COVID-19 patients with diabetes are still limited. Recently, some new information was added to this field. We performed this updated meta-analysis to reveal the underlying effect of metformin on COVID-19 patients with diabetes. We searched the PubMed, Embase and CNKI (China National Knowledge Infrastructure) databases for all articles. The odds ratio (OR) corresponding to the 95% confidence interval (95% CI) was used to assess the effect of metformin on COVID-19 patients with diabetes. The statistical heterogeneity among studies was assessed with the Q-test and I2 statistics. We collected 17 studies including 20,719 COVID-19 patients with diabetes. Our results found that metformin was associated with significantly decreased mortality and severity in COVID-19 patients with diabetes (OR = 0.64, 95% CI = 0.51–0.79 for mortality, and OR = 0.81, 95% CI = 0.66–0.99 for severity). Our meta-analysis indicated that following metformin treatment might benefit the patients with T2DM, both the mortality and severity. However, patients with severe COVID-19 should be monitored closely for the development of lactic acidosis, acidosis, and decreased kidney function.
登录
查看更多内容
DOI：
10.4158/ep-2020-0466
发表时间：
2020-10
期刊：
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
影响因子：
--
作者：
Li J;Wei Q;Li WX;McCowen KC;Xiong W;Liu J;Jiang W;Marin T;Thomas RL;He M;Gongol B;Hepokoski M;Yuan JX;Shyy JY;Xiong N;Malhotra A
通讯作者：
Malhotra A
影响因子：
44.5
作者：
Holman, Naomi;Knighton, Peter;Valabhji, Jonathan
通讯作者：
Valabhji, Jonathan
DOI：
10.1016/0197-2456(86)90046-2
发表时间：
1986-09-01
期刊：
CONTROLLED CLINICAL TRIALS
影响因子：
--
作者：
DERSIMONIAN, R;LAIRD, N
通讯作者：
LAIRD, N
影响因子：
5.2
作者：
Crouse, Andrew B;Grimes, Tiffany;Shalev, Anath
通讯作者：
Shalev, Anath
影响因子：
8.2
作者：
Cariou, Bertrand;Hadjadj, Samy;Gourdy, Pierre
通讯作者：
Gourdy, Pierre